ArticleNature cancer2020
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.
Article in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Single-cell impedance sensing on integrated circuit chip for fast tumor diagnosis.Microsystems & nanoengineering · 2026Article
- Review
- T and B cell responses against Epstein-Barr virus in primary sclerosing cholangitis.Nature medicine · 2025Article
- Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma.JAMA network open · 2025Article
- Article
- The tumor immune microenvironment in primary cutaneous melanoma.Archives of dermatological research · 2025Review
- Artemisinin Suppressed Melanoma Recurrence and Metastasis after Radical Surgery through the KIT/PI3K/AKT Pathway.International journal of biological sciences · 2025Article
- Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade.Scientific reports · 2024Article
- Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels.Frontiers in immunology · 2024Article
- Complete loss ofHGG advances · 2023Article
- Localized immune surveillance of primary melanoma in the skin deciphered through executable modeling.Science advances · 2023Article
- Evolution and modulation of antigen-specific T cell responses in melanoma patients.Nature communications · 2022Article
- Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.Brain : a journal of neurology · 2022Article
- Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection.JCI insight · 2022Article
- Perturbations of the T-cell immune repertoire in kidney transplant rejection.Frontiers in immunology · 2022Article
- Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.Frontiers in immunology · 2022Article
- Generic Multiplex Digital PCR for Accurate Quantification of T Cells in Copy Number Stable and Unstable DNA Samples.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8Science immunology · 2021Article
- Associations between T cell infiltration, T cell receptor clonality, histology and recurrence in renal cell carcinoma.Clinical and experimental immunology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 6 institutions in 4 countries.
Funding
Abstract
Primary melanomas >1 mm thickness are potentially curable by resection, but can recur metastatically. We assessed the prognostic value of T cell fraction (TCFr) and repertoire T cell clonality, measured by high-throughput-sequencing of the T cell receptor beta chain (TRB) in T2-T4 primary melanomas (n=199). TCFr accurately predicted progression-free survival (PFS) and was independent of thickness, ulceration, mitotic rate, or age. TCFr was second only to tumor thickness in its predictive value, using a gradient boosted model. For accurate PFS prediction, adding TCFr to tumor thickness was superior to adding any other histopathological variable. Furthermore, a TCFr >20% was protective regardless of tumor ulceration status, mitotic rate or presence of nodal disease. TCFr is a quantitative molecular assessment that predicts metastatic recurrence in primary melanoma patients whose disease has been resected surgically. This study suggests that a successful T cell-mediated antitumor response can be present in primary melanomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.